小児用抗てんかん薬の世界市場

小児用抗てんかん薬の世界市場は2030年までに15億米ドルに達する

2024年に11億米ドルと推定された小児用抗てんかん薬の世界市場は、2030年には15億米ドルに達し、分析期間2024-2030年のCAGRは5.7%で成長すると予測されます。本レポートで分析したセグメントの一つである第一世代抗てんかん薬は、CAGR 5.0%を記録し、分析期間終了時には8億1,490万米ドルに達すると予測されます。第二世代抗てんかん薬セグメントの成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は2億9,430万米ドル、中国はCAGR 8.9％で成長予測

米国の小児用抗てんかん薬市場は、2024年には2億9,430万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.9%として、2030年までに3億290万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と5.6%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の小児用抗てんかん薬市場- 主要動向と促進要因まとめ

なぜ小児用抗てんかん薬は世界的に臨床および規制上の注目を集めているのか？

小児てんかんの世界の増加、早期治療への注目の高まり、精密神経学の進歩により、小児を対象とした抗てんかん薬（AED）市場は急速に拡大しています。小児てんかんは、再発性の非誘発性発作を特徴とし、小児の慢性神経疾患の中で最も一般的な疾患の一つであり、乳児期または幼児期に発症することが多いです。小児てんかんの病因は、遺伝子変異や神経発達症候群から周産期の脳損傷や代謝障害に至るまで複雑であるため、年齢に応じた、有効で忍容性のある薬物療法が必要となります。従来の成人中心のAEDレジメンは、薬物動態、代謝、副作用プロファイルの違いから、小児への使用にしばしば課題をもたらします。そのため、小児に特化した製剤や投与プロトコルの開発、承認された分子に対する適応拡大が、規制上も臨床上も重視されるようになってきています。

FDAやEMAなどの組織は、小児科調査計画（PIPs）や小児科研究公正法（PREA）に基づき、小児科臨床試験を実施するよう製薬企業に奨励しており、そのインセンティブとして適応拡大や希少疾病用医薬品の指定があります。このような規制の機運は、小児の嚥下・漸増要件に対応したチュアブル錠、懸濁液、ミニ錠、口腔内崩壊錠などの剤形革新を促しています。同時に、新興市場では神経画像、遺伝子スクリーニング、脳波検査へのアクセスが増加しており、早期診断、発作分類の改善、的を絞った薬理学的介入への需要が高まっています。これらの要因により、小児てんかんは医薬品イノベーション、公衆衛生計画、介護者支援システムにとって優先順位の高い神経領域として位置づけられています。

製剤科学と医薬品パイプラインの革新は、小児の治療成績をどのように向上させているか？

製剤科学と臨床パイプラインにおける科学的進歩は、小児AEDの展望を再構築し、薬剤の忍容性、多剤併用療法、薬剤耐性に関する長年の課題に対処しています。レベチラセタム、オクスカルバゼピン、ラモトリギン、トピラマート、ブリバラセタムなどの新世代のAEDは、フェノバルビタールやフェニトインのような旧来の薬剤と比較して、安全性プロファイルが改善され、幅広いスペクトラム活性を有し、鎮静作用や認知機能の副作用が軽減されています。これらの薬剤は、経口液剤、散剤、散剤など、小児に特化した剤形での入手が可能になってきており、体重や発育段階に応じた正確な投与が可能となっています。さらに、服用スケジュールを簡略化し、服薬アドヒアランスを高め、夜間や通学時間帯における発作のブレークスルーのリスクを軽減するために、合剤（FDC）や徐放性（ER）製剤の開発も進められています。

パイプラインの面では、Dravet症候群、レノックス・ガストー症候群（LGS）、結節性硬化症複合体（TSC）など、遺伝的に定義された希少な小児てんかんの研究が進められています。カンナビジオール（CBD）、スプリペントール、フェンフルラミン、エベロリムスなどの標的治療薬は、従来のAEDが効かない発作のコントロールに有効であるとして、承認やファスト・トラック指定を獲得しつつあります。選択的ナトリウムチャネル遮断薬、GABA調節薬、遺伝子治療薬などの新しいメカニズムが、薬剤耐性てんかん（DRE）に対処し、長期的な神経発達への影響を軽減するために研究されています。また、薬理遺伝学を小児AEDの選択に組み込むことで、臨床医が代謝プロファイルや発作の表現型に基づいて治療法を調整できるようになりつつあります。このような技術革新は、発作制御を改善するだけでなく、小児神経学的治療において極めて重要な考慮事項である発達への悪影響を最小限に抑えることにもつながっています。

小児用AEDの需要はどこで高まり、どのような利害関係者が小児用AEDの採用を促進しているのか？

小児用抗てんかん薬に対する需要は、先進国市場と新興国市場の双方で高まっています。その背景には、てんかん診断率の上昇、小児神経医療サービスへのアクセスの増加、介護者の意識の高まりがあります。北米と西欧は、薬事承認、臨床試験、新規AEDの早期導入の面でリードしています。特に米国では、レベチラセタム、ラモトリギン、カンナビジオールベースの小児用承認製剤の処方件数が増加しており、償還制度や介護者の支持も後押ししています。欧州では、希少疾病用医薬品（オーファンドラッグ）パスウェイと国民医療保険が重視されているため、症候性てんかんの新しい治療法へのアクセスが容易になっています。

アジア太平洋およびラテンアメリカでは、ヘルスケアインフラの改善、官民パートナーシップ、小児専門医療により、診断および治療へのアクセスが拡大しています。インド、中国、ブラジルなどの国々では、特に国民健康保険制度や小児保健プログラムを通じて、経口懸濁型AEDや低コストのジェネリック医薬品の普及が進んでいます。病院を拠点とする小児神経科医やてんかんセンターが処方の決定において重要な役割を果たしている一方で、一般小児科医が発作の早期発見やAED管理について研修を受ける機会が増えています。また、早期治療開始、服薬アドヒアランスの向上、てんかん児の生活の質の向上を推進するため、介護者ネットワーク、てんかん財団、学校を中心とした啓発キャンペーンの役割も大きくなっています。このような利害関係者の努力の積み重ねが、十分な治療を受けていない地域における治療格差を縮小しつつ、市場の成長を促しています。

小児用抗てんかん薬市場の世界的成長の原動力は？

小児用抗てんかん薬市場の成長は、小児てんかんの有病率の増加、早期治療のための臨床ガイドラインの拡大、より優れた安全性と有効性プロファイルを有する年齢適合製剤の発売など、いくつかの要因によって牽引されています。重要な成長要因は、発作が制御されないことが長期的に発達に及ぼす影響に対する両親、小児科医、神経科医の意識が高まり、早期診断と治療開始が促されていることです。また、神経診断ツール、ゲノム検査、電子医療統合の進歩により、個別化された治療選択と薬剤反応のリアルタイムモニタリングが可能となっています。

小児の医薬品開発に対する規制上の優遇措置、希少てんかん症候群に対する希少疾病用医薬品の指定、新規AEDの迅速な承認は、イノベーションパイプラインに拍車をかけ、市場投入までの時間を短縮しています。同時に、製薬企業、学術センター、てんかん擁護団体との連携により、研究資金、臨床試験募集、介護者教育が強化されています。バイオシミラーや地域で製造されるジェネリック医薬品の出現は、特に低所得国において、購入しやすい価格とアクセスを向上させています。小児神経学が精密治療と全人的発作管理に向けて発展するにつれ、差し迫った疑問が生じます。小児抗てんかん薬の開発は、世界中のてんかん患者の臨床的な複雑さと生涯にわたるケアニーズに対応できるのだろうか。

セグメント

薬剤タイプ（第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬）、投与経路（経口剤、注射剤、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全34件）

• Abbott Laboratories
• AbbVie Inc.
• Alexza Pharmaceuticals, Inc.
• Alkem Laboratories Ltd.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bial-Portela & C.ﾂｪ, S.A.
• Cephalon, Inc.
• Dr. Reddy's Laboratories Ltd.
• Eisai Co., Ltd.
• GlaxoSmithKline plc（GSK）
• GW Pharmaceuticals plc
• H. Lundbeck A/S
• Insys Therapeutics, Inc.
• Jazz Pharmaceuticals plc
• Johnson & Johnson
• Marinus Pharmaceuticals, Inc.
• Mylan N.V.
• Novartis AG
• Ovid Therapeutics Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Anti-Epileptic Drugs for Pediatrics Market to Reach US$1.5 Billion by 2030

The global market for Anti-Epileptic Drugs for Pediatrics estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. First Generation Anti-epileptic Drugs, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$814.9 Million by the end of the analysis period. Growth in the Second Generation Anti-epileptic Drugs segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$294.3 Million While China is Forecast to Grow at 8.9% CAGR

The Anti-Epileptic Drugs for Pediatrics market in the U.S. is estimated at US$294.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$302.9 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Anti-Epileptic Drugs for Pediatrics Market - Key Trends & Drivers Summarized

Why Are Pediatric Anti-Epileptic Drugs Gaining Greater Clinical and Regulatory Attention Worldwide?

The market for anti-epileptic drugs (AEDs) targeting pediatric populations is expanding rapidly due to the rising global burden of childhood epilepsy, increased focus on early intervention, and advances in precision neurology. Pediatric epilepsy-characterized by recurrent, unprovoked seizures-is one of the most common chronic neurological disorders in children, with onset frequently occurring in infancy or early childhood. The complex etiology of pediatric epilepsy, ranging from genetic mutations and neurodevelopmental syndromes to perinatal brain injury and metabolic disorders, necessitates age-appropriate, efficacious, and tolerable drug therapies. Conventional adult-centric AED regimens often pose challenges in pediatric use due to differences in pharmacokinetics, metabolism, and side effect profiles. As a result, there is growing regulatory and clinical emphasis on developing pediatric-specific formulations, dosing protocols, and indication extensions for approved molecules.

Organizations such as the FDA and EMA are encouraging pharmaceutical companies to conduct pediatric trials under pediatric investigation plans (PIPs) and pediatric research equity acts (PREA), with incentives for label expansions and orphan drug designations. This regulatory momentum is driving formulation innovation in chewable tablets, suspensions, mini-tablets, and orally disintegrating dosage forms that accommodate pediatric swallowing and dosage titration requirements. At the same time, increasing access to neuroimaging, genetic screening, and electroencephalography (EEG) in emerging markets is facilitating earlier diagnosis, improving seizure classification, and driving demand for targeted pharmacologic interventions. These factors are repositioning pediatric epilepsy as a high-priority neurology segment for pharmaceutical innovation, public health planning, and caregiver support systems.

How Are Formulation Science and Drug Pipeline Innovation Enhancing Pediatric Treatment Outcomes?

Scientific advancements in formulation science and the clinical pipeline are reshaping the pediatric AED landscape, addressing long-standing challenges related to drug tolerability, polytherapy, and pharmacoresistance. Newer-generation AEDs-such as levetiracetam, oxcarbazepine, lamotrigine, topiramate, and brivaracetam-offer improved safety profiles, broader spectrum activity, and reduced sedative or cognitive side effects compared to older agents like phenobarbital and phenytoin. These drugs are increasingly available in pediatric-specific formats, including oral liquids, sprinkles, and dispersible tablets, which enable precise dosing based on body weight and developmental stage. Moreover, fixed-dose combinations (FDCs) and extended-release (ER) formulations are being developed to simplify dosing schedules, enhance adherence, and reduce seizure breakthrough risks during night-time or school hours.

On the pipeline front, pharmaceutical research is focusing on rare and genetically defined pediatric epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Targeted therapies such as cannabidiol (CBD), stiripentol, fenfluramine, and everolimus are gaining approval or fast-track designations due to their role in seizure control where conventional AEDs fail. Novel mechanisms-such as selective sodium channel blockers, GABA modulators, and gene-based therapies-are under investigation to address drug-resistant epilepsy (DRE) and reduce long-term neurodevelopmental impact. The integration of pharmacogenetics into pediatric AED selection is also emerging, allowing clinicians to tailor therapy based on metabolic profile and seizure phenotype. These innovations are not only improving seizure control but also minimizing adverse developmental effects, a crucial consideration in pediatric neurologic care.

Where Is Market Demand Intensifying and Which Stakeholders Are Driving Adoption of Pediatric AEDs?

Demand for pediatric anti-epileptic drugs is intensifying across both developed and emerging markets, driven by increasing epilepsy diagnosis rates, growing access to pediatric neurology services, and heightened caregiver awareness. North America and Western Europe lead in terms of regulatory approvals, clinical trial activity, and early adoption of novel AEDs. The United States, in particular, has seen growing prescription volumes for pediatric-approved formulations of levetiracetam, lamotrigine, and cannabidiol-based therapies, aided by supportive reimbursement structures and caregiver advocacy. Europe’s emphasis on orphan drug pathways and national healthcare coverage is similarly facilitating access to newer treatments for syndromic epilepsies.

In Asia-Pacific and Latin America, improvements in healthcare infrastructure, public-private partnerships, and pediatric specialty care are expanding diagnosis and treatment access. Countries such as India, China, and Brazil are seeing increased uptake of oral suspension AEDs and low-cost generics, particularly through national health insurance schemes and child health programs. Hospital-based pediatric neurologists and epilepsy centers are playing a pivotal role in prescription decision-making, while general pediatricians are increasingly being trained in early seizure identification and AED management. The role of caregiver networks, epilepsy foundations, and school-based awareness campaigns is also growing, pushing for early treatment initiation, improved medication adherence, and better quality of life for children with epilepsy. These converging stakeholder efforts are catalyzing market growth while narrowing treatment gaps in underserved regions.

What Is Driving the Global Growth of the Pediatric Anti-Epileptic Drugs Market?

The growth in the pediatric anti-epileptic drugs market is driven by several factors, including increasing prevalence of childhood epilepsy, expanded clinical guidelines for early treatment, and the launch of age-adapted drug formulations with better safety and efficacy profiles. A critical growth driver is the rising awareness among parents, pediatricians, and neurologists about the long-term developmental consequences of uncontrolled seizures, prompting earlier diagnosis and therapy initiation. Advances in neurodiagnostic tools, genomic testing, and electronic health integration are also enabling personalized treatment selection and real-time monitoring of drug response.

Regulatory incentives for pediatric drug development, orphan designations for rare epilepsy syndromes, and fast-track approvals for novel AEDs are fueling innovation pipelines and accelerating time-to-market. Simultaneously, collaborations between pharmaceutical companies, academic centers, and epilepsy advocacy groups are strengthening research funding, trial recruitment, and caregiver education. The emergence of biosimilars and regionally manufactured generics is enhancing affordability and access, particularly in lower-income countries. As pediatric neurology evolves toward precision therapeutics and holistic seizure management, a pressing question arises: Can pediatric anti-epileptic drug development keep pace with the clinical complexity and lifelong care needs of children living with epilepsy worldwide?

SCOPE OF STUDY:

The report analyzes the Anti-Epileptic Drugs for Pediatrics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs, Third Generation Anti-epileptic Drugs); Administration Route (Oral, Injectable, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Alexza Pharmaceuticals, Inc.
• Alkem Laboratories Ltd.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bial - Portela & C.ª, S.A.
• Cephalon, Inc.
• Dr. Reddy's Laboratories Ltd.
• Eisai Co., Ltd.
• GlaxoSmithKline plc (GSK)
• GW Pharmaceuticals plc
• H. Lundbeck A/S
• Insys Therapeutics, Inc.
• Jazz Pharmaceuticals plc
• Johnson & Johnson
• Marinus Pharmaceuticals, Inc.
• Mylan N.V.
• Novartis AG
• Ovid Therapeutics Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Anti-Epileptic Drugs for Pediatrics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Pediatric Epilepsy Diagnosis Rates Trigger Demand for Targeted Anti-Epileptic Therapies
  • Innovation in Age-Appropriate Drug Delivery Systems Enhances Pediatric Anti-Epileptic Care
  • Advances in Mechanism-Specific Compounds Reduce Neurocognitive Side Effects in Children
  • Rare Pediatric Epilepsy Syndromes Attract Orphan Drug Development in Anti-Epileptic Space
  • Early Intervention and Screening Initiatives Accelerate Access to Anti-Epileptic Drugs in Pediatrics
  • Clinical Trial Adaptations Tailored to Pediatric Profiles Improve Drug Safety Evaluation
  • Polytherapy Strategies Refined to Manage Refractory Epilepsy Cases in Children
  • Increasing Parental Awareness Drives Proactive Treatment of Pediatric Seizure Disorders
  • Regulatory Incentives Fuel Market Entry of Pediatric-Specific Anti-Epileptic Drug Formulations
  • Digital Health Tools Aid in Remote Monitoring of Pediatric Epilepsy Treatment Outcomes
  • Market Leaders Expand Portfolios with Child-Focused Anti-Epileptic Innovations
  • Reimbursement Frameworks in Developed Markets Boost Affordability of Pediatric Anti-Epileptics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anti-Epileptic Drugs for Pediatrics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anti-Epileptic Drugs for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for First Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for First Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for First Generation Anti-epileptic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Second Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Second Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Second Generation Anti-epileptic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Third Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Third Generation Anti-epileptic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Third Generation Anti-epileptic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Anti-Epileptic Drugs for Pediatrics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Anti-Epileptic Drugs for Pediatrics by Drug Type - First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Drug Type - Percentage Breakdown of Value Sales for First Generation Anti-epileptic Drugs, Second Generation Anti-epileptic Drugs and Third Generation Anti-epileptic Drugs for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Anti-Epileptic Drugs for Pediatrics by Administration Route - Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Administration Route - Percentage Breakdown of Value Sales for Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Anti-Epileptic Drugs for Pediatrics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION